NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimers Disease Treatment.
–News Direct– SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) — Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the…
